SCHEMBL19982190

SCHEMBL19982190

O=[N+]([O-])c1nc[nH]c1/C=C/c1ccc(O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.46
FBP1 P09467 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
GFER P55789 1/20 0.45
TAAR1 Q96RJ0 1/20 0.43
PTGS2 P35354 2/20 0.42
PTGS1 P23219 1/20 0.42
APP P05067 3/20 0.39
BACE1 P56817 3/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36
MAOB P27338 2/20 0.36
MAOA P21397 1/20 0.36
GALK1 P51570 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19982272 0.85 TAAR1 (0.43) EGFRMEN1KMT2ATAAR1PTGS2
SCHEMBL10102686 0.85 TAAR1 (0.60) FBP1MEN1KMT2ATAAR1MAPT
SCHEMBL19982086 0.83 TAAR1 (0.51) EGFRFBP1MEN1KMT2ATAAR1
SCHEMBL19982297 0.82 FBP1 (0.50) FBP1MEN1KMT2ATAAR1PTGS2
SCHEMBL22929156 0.82 MEN1 (0.53) EGFRMEN1KMT2ATAAR1PTGS2
SCHEMBL19982293 0.82 TAAR1 (0.41) FBP1MEN1KMT2ATAAR1PTGS2
SCHEMBL22929138 0.79 TAAR1 (0.39) FBP1MEN1KMT2ATAAR1PTGS2
SCHEMBL22929137 0.78 MAOA (0.44) EGFRMEN1KMT2ATAAR1PTGS1
SCHEMBL19982296 0.78 TLR4 (0.46) MEN1KMT2ATAAR1MAPTNPC1
SCHEMBL19982233 0.75 FBP1 (0.51) FBP1MEN1KMT2AGFERTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234924-A1 YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-27 US disclosed
US-20230234924-A1 YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-27 US disclosed
US-11530182-B2 YAP1 inhibitors that target the interaction of YAP1 with Oct4 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20210130297-A1 YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-05-06 US disclosed
US-10906874-B2 YAP1 inhibitors that target the interaction of YAP1 with OCT4 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2021-02-02 US disclosed
WO-2018053446-A1 YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906874-B2 YAP1 inhibitors that target the interaction of YAP1 with OCT4 YAP1, IWS1, YES1 EGFR 1288/4885FBP1 2055/4885MEN1 4141/4885
US-20210130297-A1 YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 YAP1, YES1, MYC EGFR 1116/4885FBP1 1745/4885MEN1 3702/4885
US-20230234924-A1 YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 YAP1, YES1, MYC EGFR 1336/4885FBP1 1669/4885MEN1 3614/4885
US-11530182-B2 YAP1 inhibitors that target the interaction of YAP1 with Oct4 YAP1, YES1, MYC EGFR 1116/4885FBP1 1745/4885MEN1 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.